What is it about?
CRID3 administration can inhibit inflammasome-related ASC and caspase-1, IL-1β, and IL-18 activation, which consequently suppressed M1 microglia, Th1 and Th1Th17 differentiation, and increased M2 microglia and Th2 differentiation. The early administration may be a promising therapeutic strategy for SCI.
Featured Image
Why is it important?
CRID3 may ameliorate murine SCI by inhibiting inflammasome activation, reducing proinflammatory factor production, restoring immune cell subset balance, and improving local immune microenvironment, and early administration may be a promising therapeutic strategy for SCI.
Perspectives
The early administration of CRID3 may be a promising therapeutic strategy for SCI.
He-Zuo Lü
Bengbu Medical College
Read the Original
This page is a summary of: CRID3, a Blocker of Apoptosis Associated Speck Like Protein Containing a Card, Ameliorates Murine Spinal Cord Injury by Improving Local Immune Microenvironment, SSRN Electronic Journal, January 2020, Elsevier,
DOI: 10.2139/ssrn.3569817.
You can read the full text:
Contributors
The following have contributed to this page
